Sir Demis Hassabis has hailed a multi-billion-dollar investment in the startup he founded which was spun out of Google DeepMind and focuses on leveraging AI to help drug discovery as a “massive vote of confidence”.
Isomorphic Labs said it has raised $2.1bn in a Series B funding. The funding round was led by existing investor Thrive Capital, the US VC, with participation from existing backers Alphabet, Isomorphic's parent company, and its venture captial unit, GV.
New investors include Singapore's Temasek, Google’s growth fund arm CapitalG, and the UK Sovereign AI Fund.
Hassabis, CEO and founder of Isomorphic Labs, who also heads up Google’s AI offering, said: “This funding round is a massive vote of confidence from a diverse group of top-tier international investors in our AI-first approach to drug design and development.
"Now that we have shown our approach is fundamentally sound, our focus is on scaling our technology to its full potential. This capital injection allows us to build out our drug design engine at scale, driving us forward in our mission to solve all disease."
